Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Rivertop Renewables Begins Contract Manufacturing to Scale-Up Green Chemicals

Published: Tuesday, April 02, 2013
Last Updated: Tuesday, April 02, 2013
Bookmark and Share
Demonstrated capability of breakthrough oxidation technology enables commercial-scale products and advanced testing.

Rivertop Renewables (, a Montana-based renewable chemicals company, today announced it has successfully scaled its patented process technology from the lab to pilot manufacturing. Rivertop has contracted with DTI (, a custom manufacturer of fine and specialty chemical products based in Danville, Virginia, to pilot the manufacture of Rivertop's sustainable, high performing, cost-competitive, glucarate-based products. Product made in this initial phase of contract manufacturing will be used to fulfill Rivertop's commercial contracts for bio-based corrosion inhibitors. Remaining volumes of manufactured product will be used by the company and its customers to develop and test glucarate applications in a myriad of other industrial and consumer markets.

"Demonstrating the capability of our technology is another key milestone for our company and proof point for our oxidation process," said Jere Kolstad, President of Rivertop. "Contract manufacturing is a critical step along the way to a capital-efficient technology deployment strategy that yields a high return on investment."

Commencing in February 2012, Rivertop's pilot manufacturing has produced numerous batches of glucarate-based products at approximately 850 pounds per run. DTI's unique manufacturing technologies and flexibility enabled the accurate scaling of Rivertop's platform oxidation process. Data derived from these and subsequent runs will enable Rivertop and DTI to scale to a capacity up to 10 million pounds of contract-manufactured product per year. This next scale of production is projected to come online in the fourth quarter of 2012.

"The DTI team is excited to see and support the Rivertop team in reaching another key milestone in their business strategy," said Tim Condron, CEO of DTI. "Both teams worked tirelessly and collaboratively to meet an aggressive project timeline to transition the Rivertop technology from the lab to a manufacturing environment. This is an exciting time for the Rivertop team and we are positive the market will respond well to this new technology."

In addition to starting contract manufacturing, Rivertop is currently undergoing a multi-million dollar expansion of its research and development laboratories, including the construction of a semi-works facility, at its headquarters in Missoula, Montana. Successful contract manufacturing combined with the coming semi-works will enable the company to scale directly from pilot to global scale production in the coming years, removing the need for a costly demonstration plant.

The Department of Energy (DOE) has identified glucaric acid as one of the top 12 chemicals of the future made from renewable sources. Rivertop initially plans to use its glucaric acid products as an effective and cost-competitive replacement for phosphates in the multi-billion dollar markets for global detergent builders, as well as corrosion inhibitors and chelants to protect transportation and industrial infrastructure without damaging water quality. Multiple longer-term opportunities exist in the company's research with advanced biodegradable polymers, adhesives, and other functional materials. Rivertop's platform process is capable of utilizing a wide variety of sugars to produce a large spectrum of green chemicals and bio-based products that possess a range of properties with applications in various markets.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos